|
|
 |
|
|
Today, we use the patient's own bones (autologous bones) or artificial bones to rectify major bone loss as a result of surgery, for example. However, this method is invasive and could damage the patient's body. In some cases, autologous bones are simply not available in sufficient quantity, and may delay osteoanagenesis.
As a solution, bone regenerative medicine is now attracting great attention. Research has confirmed that β-TCP is a useful tissue engineered bone carrier*1. Encouraged by these promising research findings, Olympus Biomaterial Corp. decided to enter the regenerative medicine business.
|
*1 A carrier is a material that acts as the base for cell culture.
|
We will manufacture and supply tissue engineered bones to medical institutions. The tissue engineered bones are made by culturing mesenchymal stem cells extracted from the patient's bone marrow into bone cells on β-TCP. |
|
|
|
|
 |
|
Cell Processing Center (located in the Institute of Biomedical Research and Innovation (IBRI))
We are actively engaged in research on cell culture technology at the Institute of Biomedical Research and Innovation (IBRI)*2, one of the core facilities of the Kobe Medical Industry Development Project, and will start clinical testing on tissue engineered bone material in the fall of 2005. Plans call for marketing commercial products in 2008 after obtaining MHLW approval under the Pharmaceutical Law.
|
*2 The Institute of Biomedical Research and Innovation (IBRI), one of the core facilities of the Kobe Medical Industry Development Project, has a Cell Processing Center that can safely culture human cells or tissues in conformity with GMP (Good Manufacturing Practice) for manufacturing and quality control. |
|
|
|
|
|
